Dermapharm Holding SE released preliminary financial results for the fourth quarter and the full 2025 year on Tuesday, with the figures landing at the conservative end of the company's previously issued guidance and slightly below consensus compiled by the company.
In the fourth quarter, reported sales were €296 million, representing a 2% increase compared with the same period a year earlier. That top-line result fell €17 million short of the company-compiled consensus estimate of €313 million - a shortfall of roughly 6% relative to market expectations.
Adjusted EBITDA for Q4 came in at €89 million, up 18% year-over-year. Despite the improvement, the adjusted EBITDA number missed the company-compiled consensus of €91 million by about 2%.
Margins showed notable improvement. The adjusted EBITDA margin expanded to 30.0% in the quarter from 25.9% in the prior-year period, a level the company noted as its highest since the first quarter of 2023.
On a full-year basis for 2025, Dermapharm recorded sales of €1,165 million, a 1% decline versus the prior year and 1% below the company-compiled consensus of €1,183 million. Full-year adjusted EBITDA was reported at €325 million, up 3% year-over-year, with a margin of 27.9% compared with 26.7% in 2024. The €325 million adjusted EBITDA finish was 1% under the €327 million consensus figure.
The company attributes the expansion in margins during the year to portfolio optimization and to the deliberate phase-out of unprofitable parallel import volumes. Dermapharm has indicated that audited accounts and forward-looking guidance for 2026 will be published on March 31.
Taken together, the preliminary results show modest organic improvement in profitability metrics and margin expansion, while revenue and adjusted EBITDA measures missed street expectations by small margins. Investors and market participants will have the benefit of audited statements and management guidance at the end of March to clarify the outlook for 2026.